Study Shows Gazyva® May Offer Potential New Treatment for Lupus Nephritis
A new clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis (LN) announced encouraging initial results. The study showed that Gazyva, when used in combination with standard LN therapies, helped people achieve complete renal response at one year compared to placebo plus standard therapies alone.
The Phase II trial, known as NOBILITY, is a randomized, double-blind, placebo-controlled, multi-center study. It compared the safety and efficacy of Gazyva, combined with standard of care therapies mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and corticosteroids, to placebo combined with the same standard therapies in adult patients with Class III or IV proliferative LN.
In addition to showing Gazyva’s potential to promote greater achievement of complete renal response (CRR) at 52 weeks, the study also demonstrated that Gazyva may also promote improved overall renal response (defined as complete and partial renal response) and other improved measures of disease activity as measured through blood serum lab values. NOBILITY researchers are encouraged by Gazyva’s clinical trial results, which suggest it may offer a potential new treatment option for people with LN.
Currently, there are no FDA-approved treatments for LN, a serious and potentially life-threatening condition characterized by inflammation of the kidneys, which affects up to 60% of all people with lupus. Continue to follow the Lupus Foundation of America for updates on Gazyva. Learn more about medications used to treat lupus.